The effect of low-calorie, low-carbohydrate raisin containing diet on non-alcoholic fatty liver

The effect of low-calorie, low-carbohydrate raisin containing diet on liver enzymes, liver steatosis grade, inflammatory and oxidative stress biomarkers in non-alcoholic fatty liver disease patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180413039294N1

Enrollment

Registered

2019-06-26

Start date

2019-06-15

Completion date

Unknown

Last updated

2019-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non alcoholic fatty liver. Fatty (change of) liver, not elsewhere classified

Interventions

Intervention 1: Intervention group: In this group participants receives low-calorie-low-carbohydrate diet and raisin ( as a snack , 36 gram indicating 1 unit) for 12 weeks. Intervention 2: Control gro

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: All obese patients with grade 2 or higher of non-alcoholic fatty liver The increase in liver enzymes (ALT) is more than 1.5 times normal

Exclusion criteria

Exclusion criteria: Chronic Pulmonary Disease?other liver diseases,heart attack and any chronic kidney and peptic diseases. The history of drinking alcohol. Smoking and drug use. Use of diuretics and Nonsteroidal anti-inflammatory drugs (NASID), estrogen, tamoxifen, corticosteroids and hypoglycemic agents within 3 weeks before the start of the study. Evidence of infection with viral hepatitis. Pregnancy and lactation or use contraceptive pills. Having a particular diet in the last 3 months. Having a history of weight loss surgery in the last year. Average raisin daily intake of more than half a serving in a day.

Design outcomes

Primary

Measure	Time frame
Degree of hepatic steatosis. Timepoint: At baseline and end of the study. Method of measurement: Ultrasound sonography assessment.	—

Secondary

Measure	Time frame
Liver enzymes. Timepoint: At baseline and end of the study. Method of measurement: Using biochemical method and Pars azmoon Company's Kit.;IL-6. Timepoint: At baseline and end of the study. Method of measurement: Using Enzyme-Linked Immunosorbent Assay (ELISA).;Malondialdehyde. Timepoint: At baseline and end of the study. Method of measurement: Thiobarbituric acid colorimetric method (TBARS).;Total antioxidant capacity. Timepoint: At baseline and end of the study. Method of measurement: Using the Ferric Reducing Ability of Plasma Method and based on colorimetric method.;Insulin. Timepoint: At baseline and end of the study. Method of measurement: Using Enzyme-Linked Immunosorbent Assay (ELISA).;Fasting Blood Glucose. Timepoint: At baseline and end of the study. Method of measurement: Using Enzymatic method (Glucose Oxidase) and Pars azmoon Company's kit.;Lipid profile. Timepoint: At baseline and end of the study. Method of measurement: Using Enzymatic method and Pars azmoon Company's kit.;Weight. Timepoint: At baseline and end of the study. Method of measurement: Measure with a scales.	—

Measure

Time frame

Liver enzymes. Timepoint: At baseline and end of the study. Method of measurement: Using biochemical method and Pars azmoon Company's Kit.;IL-6. Timepoint: At baseline and end of the study. Method of measurement: Using Enzyme-Linked Immunosorbent Assay (ELISA).;Malondialdehyde. Timepoint: At baseline and end of the study. Method of measurement: Thiobarbituric acid colorimetric method (TBARS).;Total antioxidant capacity. Timepoint: At baseline and end of the study. Method of measurement: Using the Ferric Reducing Ability of Plasma Method and based on colorimetric method.;Insulin. Timepoint: At baseline and end of the study. Method of measurement: Using Enzyme-Linked Immunosorbent Assay (ELISA).;Fasting Blood Glucose. Timepoint: At baseline and end of the study. Method of measurement: Using Enzymatic method (Glucose Oxidase) and Pars azmoon Company's kit.;Lipid profile. Timepoint: At baseline and end of the study. Method of measurement: Using Enzymatic method and Pars azmoon Company's kit.;Weight. Timepoint: At baseline and end of the study. Method of measurement: Measure with a scales.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactRoghaye Alboebadi

Ahvaz University of Medical Sciences

r_ebadi2011@yahoo.com+98 61 5244 3045

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026